Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Published version of a preprint

Abstract

Wee1 is a tyrosine kinase that phosphorylates and inactivates CDC2 and is involved in G2 checkpoint signaling. Because p53 is a key regulator in the G1 checkpoint, p53-deficient tumors rely only on the G2 checkpoint after DNA damage. Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition. Here, we report the discovery of a potent and selective small-molecule inhibitor of Wee1 kinase, MK-1775. This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G2 DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles. Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies. [Mol Cancer Ther 2009;8(11):2992–3000]

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-0463

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 31 references

Cited by

See all 560

Metadata

Authors
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., Itadani, H., Takahashi-Suzuki, I., Fukasawa, K., Oki, H., Nambu, T., Jiang, J., Sakai, T., Arakawa, H., Sakamoto, T., Sagara, T., Yoshizumi, T., Mizuarai, S., & Kotani, H.
Affiliations
Departments of 1Oncology, 2Pharmacology, and 3Chemistry, Banyu Tsukuba Research Institute, Merck Research Laboratories, Tsukuba, Japan
Venue
Molecular Cancer Therapeutics
Published
2009-11-01
Volume
8
Issue
11
Pages
2992-3000
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2096293110
Cited by
540
References
31
Citations by year
2026: 27 · 2025: 24 · 2024: 33 · 2023: 63 · 2022: 37 · 2021: 39 · 2020: 47 · 2019: 34 · 2018: 41 · 2017: 39 · 2016: 34 · 2015: 34 · 2014: 22 · 2013: 27 · 2012: 22
FWCI
6.50
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
WEE1, MK-1775, p53-deficient tumors, G2 checkpoint, Cdc2 phosphorylation, DNA-damaging agents, chemosensitization, gemcitabine, carboplatin, cisplatin, apoptosis, small-molecule kinase inhibitors, combination chemotherapy
MeSH terms
Animals, Antineoplastic Combined Chemotherapy Protocols, DNA Damage, Drug Synergism, Flow Cytometry, HeLa Cells, Humans, Neoplasms, Nuclear Proteins, Phosphorylation, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Pyrimidinones, Rats, Inbred F344, Rats, Nude, Tumor Suppressor Protein p53, CDC2 Protein Kinase, Apoptosis, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin B, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0463
The paper
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., Itadani, H., Takahashi-Suzuki, I., Fukasawa, K., Oki, H., Nambu, T., Jiang, J., Sakai, T., Arakawa, H., Sakamoto, T., . . . Kotani, H. (2009). Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.